Concurrent Trastuzumab and HER2/<i>neu</i>-Specific Vaccination in Patients With Metastatic Breast Cancer

Abstract

Combination therapy with trastuzumab and a HER2/neu vaccine is associated with minimal toxicity and results in prolonged, robust, antigen-specific immune responses in treated patients.